Erythromycin
Average across 13 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Alembic Pharmaceuticals Limited | generic | 12 | SUPPLYING |
| Ascend Laboratories, LLC | generic | 8 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | generic | 6 | SUPPLYING |
| Zydus Lifesciences Limited | generic | 6 | SUPPLYING |
| Cadila Pharmaceuticals Limited | unknown | 4 | SUPPLYING |
| Arbor Pharmaceuticals, Inc. | unknown | 4 | SUPPLYING |
| Orange Pharmaceuticals USA LLC | unknown | 4 | SUPPLYING |
| Wilshire Pharmaceuticals, Inc. | unknown | 4 | SUPPLYING |
| Modavar Pharmaceuticals LLC | unknown | 4 | SUPPLYING |
| Nivagen Pharmaceuticals, Inc. | unknown | 4 | SUPPLYING |
| PD-Rx Pharmaceuticals, Inc. | repackager | 3 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 3 | SUPPLYING |
| A-S Medication Solutions | repackager | 2 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit — Recalling firm: Zydus Pharmaceuticals (USA) Inc — Nationwide within the U.S
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit — Recalling firm: Zydus Pharmaceuticals (USA) Inc — Nationwide within the U.S
